



Press Release

**APR Applied Pharma Research presents its latest innovations
At the CPhI Worldwide in Frankfurt (October 24th-26th)**

Frankfurt, 24th October 2017 – **APR Applied Pharma Research s.a.** (APR), the Swiss independent developer of science driven and patent protected healthcare products, is attending the **CPhI Worldwide in Frankfurt, Germany, October 24th – 26th**, presenting company most relevant **product innovations and science driven technologies** in order to meet global business partners and establish new business relationships.

During the congress, APR is present in the Exhibition Booth n. **61B13 in Hall 6.1**, alongside Farma Industria Ticino delegation, where company literature and products presentations will be available.

“We are pleased to come back as exhibitor to the CPhI Worldwide, which allows us to introduce to the global pharmaceutical community our most relevant innovations, either products or technology platforms, such as Halykoo[®], SwitzAge[™], Nexodyn[®] and the recently patented Physiomimic[™] Technology.” said Paolo Galfetti CEO of APR. “CPhI is the perfect showcase for our progress in developing science driven and patient-centric healthcare solutions.”

Among the most relevant innovations of APR, there are the following **products and development programs**:

Physiomimic[™] Technology - A drug delivery technology platform, developed and patented by APR, engineered to allow a physiological absorption of amino acids, by mimicking the absorption kinetics of dietary proteins, whilst masking significantly amino acid taste and odor, for positive clinical outcomes and lasting compliance in aminoacidopathies management. An innovative medical food for phenylketonuria (PKU) has been developed based on the patented technology platform and formulations are being evaluated to convey benefits to other aminoacidopathies.

Nexodyn[®] - The first Active Wound Cleanser that creates an ideal Wound Microenvironment, sustaining the physiological wound healing process and favoring an optimized lesion closure, especially in chronic wounds management. Thanks to its physico-chemical properties, it also exerts an ancillary antimicrobial action on the wound surface, enhancing the reduction of the local bacterial load and actively promoting tissue regeneration. For more information, please visit <http://www.apr.ch/apr-pharma-products/medical-prescription/nexodyn-wound-healing/#nexodyn-formula>.

SwitzAge[™] - The first 100% Swiss Made Nutraceutical line, made of 8 food supplements, specifically designed to match the increasing demand for high-quality food supplements tailored on adult people health needs. Inspired from a holistic approach focused on the specific physiological needs of man and lady for a balanced well-being of body and mind along the aging natural course. For more information, please visit www.switzage.cn/en

Halykoo[®] - The babies' healthcare expert, is the first global brand offering the most comprehensive range of consumer healthcare products. Conceived and formulated applying the value of Swiss pharmaceutical expertise,



Halykoo provides science-driven pediatric solutions that perfectly combine smart deliveries, thanks to the application of the pharmaceutical technology knowledge, with advanced formulations, balanced on the physiological babies' needs. For more information, please visit: www.halykoo.com

About APR Applied Pharma Research s.a.

APR is a Swiss, independent developer of science driven, patent protected healthcare products. The Company identifies, develops and licenses, value added products designed to address patient or consumer needs in niche or rare therapeutic areas on a global basis. In particular, APR's business model is currently focused on two pillars: (i) internally developed and financed (alone or together with co-development partners) proprietary, value added products to be licensed to healthcare companies for their commercialization, and (ii) support to third party projects by offering added value R&D services under contract and fee for service arrangements. APR has a balanced pipeline of revenue generating branded products marketed in all major markets, combined with a compelling pipeline of products at different stages of development. APR has entered into licensing and partnership agreements with pharmaceutical companies in over 70 countries, with international sales on a worldwide basis.

For press releases and other company information, please visit: www.apr.ch

Contacts

APR:

PAOLO GALFETTI (CEO)

Tel: +41 91 695 70 20

paolo.galfetti@apr.ch | www.apr.ch

HAVAS PR MILAN:

Press Office

SARA BERNABOVI

T: +39 02 85457032 or email to sara.bernabovi@havaspr.com